Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1127949

	registered interest
	date	21/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	5G: Health Hazards
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what studies have been carried out to evaluate the effect of 5G on (a) pregnant women, (b) babies and (c) young children.
	tabling member constituency	Stroud
	tabling member printed	Dr David Drew
	uin	256920
	answer	answer is ministerial correction date of answer 30/05/2019 answer text <p>A considerable amount of research has been carried out on exposure to radio waves over several decades, and evidence reviews have been prepared by scientific expert groups in the United Kingdom and around the world. Among the health topics investigated is whether adverse effects can occur in relation to reproduction and development.</p><p>Public Health England (PHE) has published a webpage about exposure to the radio waves from mobile phone base stations, including those for 5G networks, at the following link:</p><p><a href="https://www.gov.uk/government/publications/mobile-phone-base-stations-radio-waves-and-health/mobile-phone-base-stations-radio-waves-and-health" target="_blank">https://www.gov.uk/government/publications/mobile-phone-base-stations-radio-waves-and-health/mobile-phone-base-stations-radio-waves-and-health</a></p><p>Based on the accumulated evidence and reviews, PHE advises that the guidelines of the International Commission on Non-Ionizing Radiation Protection (ICNIRP) should be adopted and there is no convincing evidence that radio wave exposures below the ICNIRP guideline levels cause adverse health effects. This includes effects in relation to reproduction and development.</p><p>PHE has committed to keeping the emerging evidence under review and to preparing another comprehensive review when sufficient new evidence has accumulated.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 30/05/2019 10:39:58 answering member 4455 label Biography information for Seema Kennedy
	tabling member	252 label Biography information for Dr David Drew

1127893

	registered interest
	date	21/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Mental Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential merits of including in the mandatory part of every diabetes appointment a question on the mental wellbeing of a patient.
	tabling member constituency	Ealing Central and Acton
	tabling member printed	Dr Rupa Huq
	uin	257108
	answer	answer is ministerial correction date of answer 30/05/2019 answer text <p>NHS England has informed us that is has not assessed the case for mandatory inclusion of this question in every diabetes appointment. The NHS Long Term Plan committed to increasing the provision of mental health support for all patients who require it and NHS England is currently taking forward a number of initiatives to deliver this for patients including for those living with diabetes.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 30/05/2019 10:57:05 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4511 label Biography information for Dr Rupa Huq

1127749

	registered interest
	date	21/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: BioMarin
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the progress of talks on procuring medicines between the NHS and Bio Marin.
	tabling member constituency	Gloucester
	tabling member printed	Richard Graham
	uin	256971
	answer	answer is ministerial correction date of answer 30/05/2019 answer text <p>We have made no such assessment. Discussions about commercial agreements for medicines are rightly held between NHS England as an independent body and the manufacturer concerned. The Department plays no role in such discussions.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 30/05/2019 10:48:36 answering member 4455 label Biography information for Seema Kennedy
	tabling member	3990 label Biography information for Richard Graham

1127772

	registered interest
	date	21/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether the review of the methods for the NICE Technology Appraisal Programme referred to in the 2019 voluntary scheme for branded medicines pricing and access will include support for earlier patient access to innovative medicines.
	tabling member constituency	Bolton West
	tabling member printed	Chris Green
	uin	257056
	answer	answer is ministerial correction date of answer 30/05/2019 answer text <p>The National Institute for Health and Care Excellence (NICE) is in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations. Scoping will involve patient organisations and other relevant stakeholders, including industry. The Voluntary Scheme for Branded Medicines Pricing and Access sets out the Department’s expectation that that any future changes to NICE methods and processes would support faster adoption of the most clinically and cost effective medicines. Additional detail and more information will be made available on the NICE website in due course.</p><p>The 2019 Voluntary Scheme also states that NICE will adopt the principle of appraisal timelines for non-oncology treatments matching the faster timescales for oncology treatments, subject to the evidence base for the product being sufficiently developed to enable a NICE appraisal with the same level of rigour and certainty as would be expected currently.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 30/05/2019 10:52:06 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4398 label Biography information for Chris Green